Free Daily Podcast Summary
CME in Minutes: Education in Oncology & Hematology: Daily Summaries Delivered
by Answers in CME
Get answers in 25 minutes or less from world-class experts and earn CME/CE credit with CME in Minutes: Education in Oncology & Hematology by Answers in CME. Benefit from digests of latest advancements, thoughtful case studies, and nuanced perspectives. Inspiring and engaging programs designed for oncologists and hematologists to cover the diagnosis, staging, treatment, follow-up, and clinical management of tumors and hematological malignancies. Earning your CME/CE credits has never been faster or easier. Visit the URL for each individual program to request continuing education credit or access the slides.
Latest Episodes
The most recent episodes — sign up to get AI-powered summaries of each one.
- Yesterday26 min
Improving Response Durability in Later-Line Metastatic Colorectal Cancer: Clinical Insights and Real-World Evidence
Please visit answersincme.com/860/103518989-replay3 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by John Strickler, MD and Chiara Cremolini, MD, PhD. In this activity, experts in metastatic colorectal cancer (mCRC) discuss real-world evidence and clinical insights related to durable responses and long-term benefits in later-line care. Upon completion of this activity, participants should be better able to: Propose treatment plans based on predictors of durable benefit and real-world evidence.
- 2 days ago1h 8m
From Surgery to Systemic Therapy: A Collaborative Discussion on CSCC Neoadjuvant and Adjuvant Immunotherapy
Please visit answersincme.com/860/MED-ONC-03814-replay to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Neil D. Gross, MD, FACS; Nikhil I. Khushalani, MD; and Emily S. Ruiz, MD, MPH. In this activity, leading skin cancer experts guide an interactive, multidisciplinary case-based discussion on optimizing (neo)adjuvant immunotherapy for high-risk, resectable cutaneous squamous cell carcinoma (CSCC). Upon completion of this activity, participants should be better able to: Apply the latest clinical trial data and guideline recommendations to treatment planning for patients with high-risk, resectable CSCC; Recognize when to incorporate systemic neoadjuvant and adjuvant immunotherapy in patients with CSCC based on clinical and pathological features; and Propose strategies to optimize care for patients with high-risk CSCC through the evidence-based use of neoadjuvant and adjuvant immunotherapy within multidisciplinary care plans.
- 3 days ago1h 7m
Optimizing Care in Perioperative Immunotherapy for Gastric/Gastroesophageal Junction Adenocarcinoma: Case-Based Insights and Multidisciplinary Collaboration
Please visit answersincme.com/860/102331945-replay to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Elizabeth Smyth, MD, FRCP and Daniela Molena, MD. In this activity, experts in gastric/gastroesophageal junction adenocarcinoma discuss the latest evidence and practical strategies for optimizing the treatment of resectable gastric (G)/gastroesophageal junction (GEJ) adenocarcinoma with perioperative immunotherapy. Upon completion of this activity, participants should be better able to: Evaluate the evidence supporting the integration of perioperative immunotherapy (IO) in the treatment of resectable gastric (G)/gastroesophageal junction (GEJ) adenocarcinoma; Analyze the role of biomarkers in decision-making for perioperative IO in resectable G/GEJ adenocarcinoma; and Outline multidisciplinary strategies for optimizing the care of patients receiving perioperative IO for resectable G/GEJ adenocarcinoma.
- 1 weeks ago32 min
From Backbone to Strategy: The Foundation of Sequential Care in EGFR-Mutated NSCLC
Please visit answersincme.com/860/103117485-replay1 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Prof. Solange Peters, MD, PhD; and Pasi A. Jänne, MD, PhD. In this activity, experts in EGFR-mutated advanced non–small-cell lung cancer (NSCLC) discuss practical strategies for optimizing first-line testing and treatment selection. Upon completion of this series, participants should be better able to: Interpret updated evidence and recommendations regarding first-line testing and treatment selection for patients with advanced EGFR-mutated NSCLC; and Discuss the role of emerging therapies in advanced EGFR-mutated NSCLC, applying insights from tumor biology to optimize sequential treatment decisions.
- 1 weeks ago1h 9m
From Evidence to Impact: Leveraging the Latest Data to Elevate Standards and Patient Outcomes in mHSPC
Please visit answersincme.com/860/101834101-replay to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Simpa S. Salami, MD, MPH; and Neal D. Shore, MD, FACS. In this activity, experts in prostate cancer discuss new evidence for individualized, evidence-based treatment strategies in metastatic hormone-sensitive disease. Upon completion of this activity, participants should be better able to: Evaluate the clinical implications of the most recent data informing the standard of care treatment options for mHSPC; Integrate patient-, disease-, and therapy-related factors to develop individualized, evidence-based treatment strategies for mHSPC; and Design patient-centered care approaches that balance the benefit and risk of treatment to optimize outcomes in mHSPC.
- 2 weeks ago15 min
Translating Evidence Into Practice: Optimizing Chemotherapy-Free Intervals and Sequencing in mCRC
Please visit answersincme.com/TNM860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Richard Kim, MD. In this activity, an expert in oncology discusses when and how to sequence later-line and chemotherapy-free therapies in metastatic colorectal cancer (mCRC). Upon completion of this activity, participants should be better able to: Evaluate factors influencing a treatment switch from cytotoxic agents for patients with stable metastatic colorectal cancer (mCRC); Formulate practical approaches for transitioning from chemotherapy to tyrosine kinase inhibitor (TKI) treatment in later-line settings for patients with mCRC; and Describe strategies to prolong chemotherapy-free disease control with TKIs.
- 2 weeks ago26 min
Oncology - Pathology Dialogues: Evolving Diagnostic Pathways to Expand Treatment of Extrapulmonary Neuroendocrine Neoplasms
Please visit answersincme.com/KJW860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Aman Chauhan, MD and Rhonda K. Yantiss, MD. In this activity, experts in medical oncology and pathology discuss identification and treatment of extrapulmonary neuroendocrine carcinomas and extrapulmonary neuroendocrine tumors. Upon completion of this activity, participants should be better able to: Differentiate extrapulmonary neuroendocrine carcinoma (EP-NEC) from extrapulmonary neuroendocrine tumors (EP-NETs); Identify diagnostic and pathological approaches to improve the recognition and accurate classification of EP-NEC and EP-NET; Evaluate emerging clinical data on DLL3-targeting bispecific TCE agents in the treatment of EP-NEC and EP-NET; and Formulate evidence-based strategies to integrate DLL3-targeting bispecific TCE therapies into evolving treatment paradigms for EP-NEC and EP-NET.
- 3 weeks ago18 min
Mastering Evolving Standards in Resectable HNSCC: A Case-Based Discussion to Elevate Pre- and Postoperative Care
Please visit answersincme.com/DDT860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Robert Haddad, MD. In this activity, an expert in medical oncology discusses locally advanced head and neck squamous cell carcinoma (LA HNSCC). Upon completion of this activity, participants should be better able to: Discuss the clinical implications of the latest data for approved and recommended regimens for resectable LA HNSCC in the pre- and postoperative settings; Outline strategies to integrate immunotherapy into pre- and postoperative settings for resectable LA HNSCC, in the context of conventional treatment; and Apply multidisciplinary team approaches to effectively manage patients with LA HNSCC across pre- and postoperative treatment phases.
About CME in Minutes: Education in Oncology & Hematology
Get answers in 25 minutes or less from world-class experts and earn CME/CE credit with CME in Minutes: Education in Oncology & Hematology by Answers in CME. Benefit from digests of latest advancements, thoughtful case studies, and nuanced perspectives. Inspiring and engaging programs designed for oncologists and hematologists to cover the diagnosis, staging, treatment, follow-up, and clinical management of tumors and hematological malignancies. Earning your CME/CE credits has never been faster or easier. Visit the URL for each individual program to request continuing education credit or access the slides.
Customized Recaps
AI-powered recaps with compact key takeaways, quotes, and insights.
Straight to Your Inbox
Get key takeaways from CME in Minutes: Education in Oncology & Hematology in a 5-minute read.
Save Hours Every Week
Stay current on your favorite podcasts without falling behind.
Frequently Asked Questions
What is Podzilla's CME in Minutes: Education in Oncology & Hematology daily summary?
It's a free AI-powered email that summarizes new episodes of CME in Minutes: Education in Oncology & Hematology as soon as they're published. You get the key takeaways, notable quotes, and links & mentions — all in a quick read.
How does the CME in Minutes: Education in Oncology & Hematology podcast summary work?
When a new episode drops, our AI transcribes and analyzes it, then generates a personalized summary tailored to your interests and profession. It's delivered to your inbox every morning.
Is this an official CME in Minutes: Education in Oncology & Hematology product?
No. Podzilla is an independent service that summarizes publicly available podcast content. We're not affiliated with or endorsed by Answers in CME.
Can I get summaries of other podcasts too?
Absolutely! The free plan covers up to 3 podcasts. Upgrade to Pro for 15, or Premium for 50. Browse our full catalog at /podcasts.
How often does CME in Minutes: Education in Oncology & Hematology release new episodes?
CME in Minutes: Education in Oncology & Hematology publishes every few days. Our AI generates a summary within hours of each new episode.
What topics does CME in Minutes: Education in Oncology & Hematology cover?
CME in Minutes: Education in Oncology & Hematology covers topics including Science, Medicine, Fitness, Health & Fitness, Life Sciences. Our AI identifies the specific themes in each episode and highlights what matters most to you.
Start getting CME in Minutes: Education in Oncology & Hematology summaries tomorrow morning.
Free forever for up to 3 podcasts. No credit card required.
Free forever for up to 3 podcasts. No credit card required.